# US 10,478,447 B2 · Antiviral supplement formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,447 B2
- Document ID: US10478447B2
- Status: Granted
- Kind: B2
- Application number: 15/882,832
- Filed: 2018-01-29
- Published: 2018-09-13
- Granted: 2019-11-19
- Earliest claimed: 2008-11-04
- Assignees: Vymedic, LLC
- Applicants: Vymedic, LLC
- Inventors: Kenneth E. Phillips; Cynthia A. Winning
- Web page: https://patentgrep.com/patent/US10478447B2

## CPC

- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/221: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.

## Claims

### Claim 1

A method of treating a viral infection in a subject in need thereof comprising administering to the subject a dosage form comprising a therapeutically effective amount of a composition comprising a lysine in a single dose range of from about 1,000 mg to about 5,000 mg, an ascorbic compound, a flavonoid glycoside, wherein the flavonoid glycoside comprises hesperidin and rutin, a threonine, a taurine and a pyridoxine, and wherein the viral infection is selected from the group consisting of an influenza virus infection and a non-polio enterovirus infection.

### Claim 2 (depends on 1)

The method of claim 1, wherein the influenza virus infection is selected from the group consisting of an influenza A, influenza B, and influenza C virus infection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dosage form is selected from the group consisting of powder, capsule, lozenge, troche, tablet, liquid, or caplet.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage form is a solid dosage form.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage form is a chewable form.

### Claim 6 (depends on 1)

The method of claim 1, wherein the lysine is selected from L-lysine, L-lysine monohydrochloride, L-lysine dihydrochloride, L-lysine succinate, L-lysine glutamate, and L-lysine orotate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ascorbic compound is selected from one or more of ascorbic acid, calcium ascorbate, magnesium ascorbate, potassium ascorbate, sodium ascorbate, manganese ascorbate, zinc ascorbate, iron ascorbate, copper ascorbate, boron ascorbate, molybdenum ascorbate, chromium ascorbate, ascorbyl palmitate, ascorbyl arachidonate, ascorbyl stearate, ascorbyl linoleate, ascorbyl linoleneate, and ascorbyl oleate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the flavonoid glycoside comprises hesperidin and rutin in about a 1:1 weight ratio.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises L-lysine monohydrochloride, ascorbic acid, calcium ascorbate, niacinamide ascorbate, ascorbyl palmitate, hesperidin, rutin, pyridoxine hydrochloride, threonine, and taurine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition further comprises calcium ascorbate, niacinamide ascorbate, and ascorbyl palmitate.

### Claim 11

A method to decrease the severity or duration of symptoms of a viral infection in a subject in need thereof comprising administering to the subject a dosage form comprising a therapeutically effective amount of a composition comprising a lysine in a single dose range of from about 1,000 mg to about 5,000 mg, an ascorbic compound, a flavonoid glycoside, wherein the flavonoid glycoside comprises hesperidin and rutin, a threonine, a taurine and a pyridoxine, wherein the viral infection is selected from the group consisting of an influenza virus infection and a non-polio enterovirus infection.

### Claim 12 (depends on 11)

The method of claim 11, wherein the influenza virus infection is selected from the group consisting of influenza A, influenza B, and influenza C virus infection.

### Claim 13 (depends on 11)

The method of claim 11, wherein the dosage form is selected from the group consisting of powder, capsule, lozenge, troche, tablet, liquid, or caplet.

### Claim 14 (depends on 11)

The method of claim 11, wherein the dosage form is a solid dosage form.

### Claim 15 (depends on 11)

The method of claim 11, wherein the dosage form is a chewable form.

### Claim 16 (depends on 11)

The method of claim 11, wherein the lysine is selected from L-lysine, L-lysine monohydrochloride, L-lysine dihydrochloride, L-lysine succinate, L-lysine glutamate, and L-lysine orotate.

### Claim 17 (depends on 11)

The method of claim 11, wherein the ascorbic compound is selected from one or more of ascorbic acid, calcium ascorbate, magnesium ascorbate, potassium ascorbate, sodium ascorbate, manganese ascorbate, zinc ascorbate, iron ascorbate, copper ascorbate, boron ascorbate, molybdenum ascorbate, chromium ascorbate, ascorbyl palmitate, ascorbyl arachidonate, ascorbyl stearate, ascorbyl linoleate, ascorbyl linoleneate, and ascorbyl oleate.

### Claim 18 (depends on 11)

The method of claim 11, wherein the flavonoid glycoside comprises hesperidin and rutin in about a 1:1 weight ratio.

### Claim 19 (depends on 11)

The method of claim 11, wherein the composition comprises L-lysine monohydrochloride, ascorbic acid, calcium ascorbate, niacinamide ascorbate, ascorbyl palmitate, hesperidin, rutin, pyridoxine hydrochloride, threonine, and taurine.

### Claim 20 (depends on 19)

The method of claim 19, wherein the composition further comprises calcium ascorbate, niacinamide ascorbate, and ascorbyl palmitate.

### Claim 21 (depends on 11)

The method of claim 11, wherein the symptoms are selected from the group consisting of runny nose, sneezing, stuffy nose, body aches, fatigue, fever, cough, sore throat, and headache.

### Claim 22 (depends on 21)

The method of claim 21, wherein the administering is performed at the first sign of flu-like illness indicated by one or more of the symptoms, at intervals selected from the group consisting of every four waking hours, every six waking hours, and twice a day, until symptoms are resolved.